1474 related articles for article (PubMed ID: 23683750)
21. Correlation between outcome and extent of residual disease in the sentinel node after neoadjuvant chemotherapy in clinically fine-needle proven node-positive breast cancer patients.
Canavese G; Tinterri C; Carli F; Garrone E; Spinaci S; Della Valle A; Barbieri E; Marrazzo E; Bruzzi P; Dozin B
Eur J Surg Oncol; 2021 Aug; 47(8):1920-1927. PubMed ID: 33972144
[TBL] [Abstract][Full Text] [Related]
22. Sentinel lymph node biopsy after neoadjuvant chemotherapy in a patient with operable breast cancer.
Hino M; Sano M; Sato N; Homma K
Surg Today; 2008; 38(7):585-91. PubMed ID: 18612781
[TBL] [Abstract][Full Text] [Related]
23. Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies.
Vriens BEPJ; Keymeulen KBMI; Kroep JR; Charehbili A; Peer PG; de Boer M; Aarts MJB; Heuts EM; Tjan-Heijnen VCG;
Oncotarget; 2017 Jul; 8(28):46557-46564. PubMed ID: 28177921
[TBL] [Abstract][Full Text] [Related]
24. De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study.
Simons JM; Koppert LB; Luiten EJT; van der Pol CC; Samiei S; de Wilt JHW; Siesling S; Smidt ML
Breast Cancer Res Treat; 2020 Apr; 180(3):725-733. PubMed ID: 32180074
[TBL] [Abstract][Full Text] [Related]
25. Ultrasound-Guided Restaging and Localization of Axillary Lymph Nodes After Neoadjuvant Chemotherapy for Guidance of Axillary Surgery in Breast Cancer Patients: Experience with Activated Charcoal.
Kim WH; Kim HJ; Jung JH; Park HY; Lee J; Kim WW; Park JY; Chae YS; Lee SJ
Ann Surg Oncol; 2018 Feb; 25(2):494-500. PubMed ID: 29134374
[TBL] [Abstract][Full Text] [Related]
26. Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy.
Cohen LF; Breslin TM; Kuerer HM; Ross MI; Hunt KK; Sahin AA
Am J Surg Pathol; 2000 Sep; 24(9):1266-72. PubMed ID: 10976701
[TBL] [Abstract][Full Text] [Related]
27. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation.
Gimbergues P; Abrial C; Durando X; Le Bouedec G; Cachin F; Penault-Llorca F; Mouret-Reynier MA; Kwiatkowski F; Maublant J; Tchirkov A; Dauplat J
Ann Surg Oncol; 2008 May; 15(5):1316-21. PubMed ID: 18311507
[TBL] [Abstract][Full Text] [Related]
28. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK;
JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169
[TBL] [Abstract][Full Text] [Related]
29. Patterns of Failure in Women Who Have Residual Nodal Disease After Neoadjuvant Chemotherapy for Breast Cancer According to Extent of Lymph Node Surgery.
Kozak MM; Horst KC; Gutkin PM; Jacobson CE; Walck E; von Eyben R; Dirbas FM
Clin Breast Cancer; 2020 Oct; 20(5):431-438. PubMed ID: 32522481
[TBL] [Abstract][Full Text] [Related]
30. Ten-year report on axillary recurrence after negative sentinel node biopsy for breast cancer from the Swedish Multicentre Cohort Study.
de Boniface J; Frisell J; Bergkvist L; Andersson Y;
Br J Surg; 2017 Feb; 104(3):238-247. PubMed ID: 28052310
[TBL] [Abstract][Full Text] [Related]
31. Sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy.
Pecha V; Kolarik D; Kozevnikova R; Hovorkova K; Hrabetova P; Halaska M; Sottner O; Trnkova M; Petruzelka L; Kolarova H
Cancer; 2011 Oct; 117(20):4606-16. PubMed ID: 21437896
[TBL] [Abstract][Full Text] [Related]
32. Targeted axillary dissection with preoperative tattooing of biopsied positive axillary lymph nodes in breast cancer.
Gatek J; Petru V; Kosac P; Ratajsky M; Duben J; Dudesek B; Jancik P; Zabojnikova M; Katrusak J; Opelova P; Podrazska L; Vazan P; Kudlova P; Holik P; Melichar B; Vrana D
Neoplasma; 2020 Nov; 67(6):1329-1334. PubMed ID: 32749847
[TBL] [Abstract][Full Text] [Related]
33. Sentinel lymph node biopsy is a reliable method for lymph node evaluation in neoadjuvant chemotherapy-treated patients with breast cancer.
Koslow SB; Eisenberg RE; Qiu Q; Chen Z; Swistel A; Shin SJ
Am Surg; 2014 Feb; 80(2):171-7. PubMed ID: 24480218
[TBL] [Abstract][Full Text] [Related]
34. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
[TBL] [Abstract][Full Text] [Related]
35. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
36. Is Nodal Clipping Beneficial for Node-Positive Breast Cancer Patients Receiving Neoadjuvant Chemotherapy?
Montagna G; Lee MK; Sevilimedu V; Barrio AV; Morrow M
Ann Surg Oncol; 2022 Oct; 29(10):6133-6139. PubMed ID: 35902495
[TBL] [Abstract][Full Text] [Related]
37. Incidence of axillary recurrence in 344 sentinel node negative breast cancer patients after intermediate follow-up. A prospective study into the accuracy of sentinel node biopsy in breast cancer patients.
Heuts EM; van der Ent FW; Hulsewé KW; Heeren PA; Hoofwijk AG
Acta Chir Belg; 2007 Jun; 107(3):279-83. PubMed ID: 17685253
[TBL] [Abstract][Full Text] [Related]
38. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
Classe JM; Loaec C; Gimbergues P; Alran S; de Lara CT; Dupre PF; Rouzier R; Faure C; Paillocher N; Chauvet MP; Houvenaeghel G; Gutowski M; De Blay P; Verhaeghe JL; Barranger E; Lefebvre C; Ngo C; Ferron G; Palpacuer C; Campion L
Breast Cancer Res Treat; 2019 Jan; 173(2):343-352. PubMed ID: 30343457
[TBL] [Abstract][Full Text] [Related]
39. A prospective feasibility study of sentinel node biopsy by modified Indigocarmine blue dye methods after neoadjuvant chemotherapy for breast cancer.
Kida K; Ishikawa T; Yamada A; Shimizu D; Tanabe M; Sasaki T; Ichikawa Y; Endo I
Eur J Surg Oncol; 2015 Apr; 41(4):566-70. PubMed ID: 25650249
[TBL] [Abstract][Full Text] [Related]
40. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up.
Kahler-Ribeiro-Fontana S; Pagan E; Magnoni F; Vicini E; Morigi C; Corso G; Intra M; Canegallo F; Ratini S; Leonardi MC; La Rocca E; Bagnardi V; Montagna E; Colleoni M; Viale G; Bottiglieri L; Grana CM; Biasuz JV; Veronesi P; Galimberti V
Eur J Surg Oncol; 2021 Apr; 47(4):804-812. PubMed ID: 33092968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
